NASDAQ$BMEA
Biomea Fusion Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Reported financial results for the second quarter of 2021 and provided business highlights.
Biomea Fusion reported a net loss attributable to common stockholders of $8.399 million for the second quarter of 2021. The company completed IND-enabling studies for BMF-219 and is on track to complete IND submission for Phase I/II study of BMF-219.
- Completed investigational new drug (“IND”) enabling studies for lead program, BMF-219.
- Continued to advance ongoing preclinical studies of BMF-219 in a number of menin-dependent liquid and solid tumors.
- Initiated pathway validation studies in type 2 diabetes.
- Strengthened Board of Directors with appointment of Sumita Ray, J.D.
Headline financials
Revenue & EPS history
Biomea Fusion · Revenue · Quarterly
$1.07B
Forward guidance
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements”.
Tailwinds
- Potential safety, efficacy, and continued development of BMF-219
- Timing for completing the IND filing or starting the clinical development
- Building out our proprietary irreversible platform
- Progress made in early-stage small pipeline molecules through their preclinical development
- Timing for nominating development candidates in each program
Headwinds
- Success, cost, and timing of the Company’s product candidate development activities and planned IND-enabling and clinical trials
- Company’s ability to execute on its strategy
- Regulatory developments in the United States
- Company’s ability to fund operations
- Impact that the current COVID-19 pandemic will have on the Company’s clinical trials and pre-clinical studies, supply chain, and operations
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports · overlaid with Q2 2021
+5.2%
Avg return
Earnings day
+3.3%
Avg return
5 days after
+3.0%
Avg return
30 days after
40%
8 / 20 earnings
Positive
+109.7%
Q4 2022
Best reaction
-16.7%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +15.3% | -13.5% | -23.7% | |
| Q3 2025 | -0.7% | -4.3% | -21.0% | |
| Q2 2025 | +0.6% | -3.2% | +21.5% | |
| Q1 2025 | -1.3% | -4.6% | +73.0% | |
| Q4 2024 | +1.2% | -7.8% | -8.7% | |
| Q3 2024 | -16.7% | -27.2% | -43.4% | |
| Q1 2024 | +6.7% | +3.7% | -9.1% | |
| Q4 2023 | -14.4% | -14.8% | -22.6% | |
| Q3 2023 | -6.8% | -7.9% | +16.3% | |
| Q2 2023 | -2.4% | -9.3% | -22.2% | |
| Q1 2023 | -3.3% | +2.6% | +12.5% | |
| Q4 2022 | +109.7% | +101.0% | +84.6% | |
| Q3 2022 | -15.6% | -29.4% | -43.3% | |
| Q2 2022 | +3.3% | +11.8% | +8.5% | |
| Q1 2022 | +35.2% | +69.4% | +127.2% | |
| Q4 2021 | -13.8% | -7.7% | -36.2% | |
| Q3 2021 | +7.6% | +2.0% | -7.9% | |
| Q2 2021 | -0.6% | -11.0% | -3.4% | |
| Q1 2021 | -0.3% | +7.9% | -21.4% | |
| Q4 2020 | -0.3% | +7.9% | -21.4% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro